Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 04-oct-2026 · last seen 04-oct-2026

uPAR-Targeting Bispecific T-Cell Engager (GFD-CD3) Senolytic

Current understanding

A GFD-CD3 bispecific T-cell engager redirects endogenous T cells against uPAR-expressing senescent cells, eliminating them and alleviating age-related pathologies in aged mice and non-human primates when dosing is titrated against serum aminotransferase activity as a hepatotoxicity biomarker [animal-model]. Positioned as a more dose-titratable alternative to uPAR-directed senolytic CAR-T cells, with safety-monitor-guided dosing as its distinguishing feature [mechanism-plausible]. No human efficacy or safety data yet.

Evidence log

Open questions

Related

Contributing findings

pubmed preclinical
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
01-oct-2026 novelty 4 per-area 4 introduces

build build 880 · 2bcef25 · 2026-11-18